We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · June 29, 2022

Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19

The Lancet Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Respir Med 2022 Jun 07;[EPub Ahead of Print], H Montgomery, FDR Hobbs, F Padilla, D Arbetter, A Templeton, S Seegobin, K Kim, JAS Campos, RH Arends, BH Brodek, D Brooks, P Garbes, J Jimenez, GCKW Koh, KW Padilla, K Streicher, RM Viani, V Alagappan, MN Pangalos, MT Esser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading